Interviews - In an exclusive video interview with PropThink.com, Michael Bailey, Chief Commercial Officer of AVEO Pharmaceuticals (NASDAQ:AVEO), explains the benefits of AVEO’s Phase III drug candidate … Continue Reading
Read now- Arena Pharmaceuticals is trading higher on a Bloomberg article highlighting that the company could be acquired. The July 8th article notes that FDA approval of … Continue Reading
Read now- In a letter to shareholders today, QLT’s (NASDAQ: QLTI) recently elected Board of Directors announced major changes to the business including the reduction of 146 … Continue Reading
Read nowInterviews - In an exclusive video interview with PropThink.com, Ablynx (EBR:ABLX)(OTC:ABLYF) CEO Dr. Edwin Moses discusses the company’s platform Nanobody technology – 1/10th the size of traditional … Continue Reading
Read nowInterviews - In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF) CEO Patrik De Haes discusses the company’s pending FDA and EMA approvals of ocriplasmin, a treatment for … Continue Reading
Read nowInterviews - Ambu (CPH:AMBU-B) President and CEO Lars Marcher discusses Ambu’s global sales position and growth strategy in an exclusive interview with PropThink.com. According to Marcher, Ambu … Continue Reading
Read nowInterviews - Zealand Pharma (ZEAL.CO) President and CEO Dr. David Solomon details timeframes in the development of lixisenatide, a treatment for type-2 diabetes licensed to Sanofi (SNY), … Continue Reading
Read now